 BRISBANE, Calif., Jan. 20, 2022 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager, TriKE protein biologic technology platform, announced today that Dr. Greg Berk, President of RD, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. 